256417-10-4

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Difluoro-4-methoxybenzaldehyde is used as a building block for the synthesis of complex pharmaceutical compounds. Its unique structure and reactivity make it a valuable component in the development of new drugs with improved efficacy and selectivity.
Used in the Synthesis of G Protein-Coupled Receptor 40 Agonists:
2,6-Difluoro-4-methoxybenzaldehyde is used as a key intermediate in the preparation of potent and orally available G protein-coupled receptor 40 (GPR40) agonists. These agonists are important for the treatment of type 2 diabetes, as they help to improve insulin secretion and glucose homeostasis in patients.

InChI:InChI=1/C8H6F2O2/c1-12-5-2-7(9)6(4-11)8(10)3-5/h2-4H,1H3

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 4885-02-3 Dichloromethyl methyl ether 
• 93343-10-3 3,5-difluoroanisol 
• 617-84-5 N-formyldiethylamine 
• 372-18-9 1,3-Difluorobenzene 
• 65611-08-7 dichloromethyl propyl ether 
• 5312-73-2 dichloromethyl n-butyl ether 
• 352-32-9 p-fluorotoluene 
• 5374-05-0 (dichloromethoxy)ethane 
• 202865-61-0 1-bromo-2,6-difluoro4-methoxybenzene 

Downstream Products

• 858114-78-0 ethyl (2E)-3-(2,6-difluoro-4-methoxyphenyl)acrylate 
• 1000197-92-1 phenylmethyl N-[3-[4-[3-chloro-1,6-dihydro-1-[(2S)-2-methylbutyl]-6-oxo-5-(1H-pyrazol-1-yl)-2-pyrazinyl]-3,5-difluorophenoxy]propyl]-N-methylcarbamate 
• 1193350-51-4 2-bromo-4-chloro-5-(2,6-difluoro-4-methoxyphenyl)-1-(3-fluorophenyl)-1H-imidazole 
• 1193350-43-4 4-chloro-5-(2,6-difluoro-4-methoxyphenyl)-1-(3-fluorophenyl)-1H-imidazole 
• 1193354-78-7 5-[2-bromo-4-chloro-5-(2,6-difluoro-4-methoxyphenyl)-1H-imidazol-1-yl]-2-(trifluoromethyl)pyridine 
• 1193512-02-5 5-[5-(2,6-difluoro-4-methoxyphenyl)-1H-imidazol-1-yl]-2-(trifluoromethyl)pyridine 
• 1193580-64-1 5-[4-chloro-5-(2,6-difluoro-4-methoxyphenyl)-1H-imidazol-1-yl]-2-(trifluoromethyl)pyridine 
• 1193354-58-3 2-chloro-5-(2,6-difluoro-4-methoxyphenyl)-1-(3,5-dimethoxyphenyl)-4-methyl-1H-imidazole 
• 1193353-98-8 5-(2,6-difluoro-4-methoxyphenyl)-1-(3,5-dimethoxyphenyl)-4-methyl-1H-imidazole 
• 1203662-96-7 2,6-difluoro-4-methoxy-3-nitro-benzaldehyde 

Relevant academic research and scientific papers

PIPERIDINES OR PIPERIDONES SUBSTITUTED WITH UREA AND PHENYL

The present invention relates to a compound according to general formula (I) which acts as a modulator of FPR2 and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by FPR2.

Direct formylation of fluorine-containing aromatics with dichloromethyl alkyl ethers

Formylations of fluorine-containing aromatic compounds with dichloromethyl alkyl ethers have been investigated. Dichloromethyl propyl ether and dichloromethyl butyl ether have been applied for the formylation of fluorine-containing anisoles to give the corresponding aldehydes in good yields. Application of these ethers is preferable to that of methyl ether, which is prepared from volatile methyl formate. Reaction of fluorine-containing phenols with these dichloromethyl alkyl ethers did not give salicylaldehyde derivatives, leading instead to corresponding aryl formates in high yields. A plausible mechanism is discussed.

Barbier Continuous Flow Preparation and Reactions of Carbamoyllithiums for Nucleophilic Amidation

An ambient temperature continuous flow method for nucleophilic amidation and thioamidation is described. Deprotonation of formamides by lithium diisopropylamine (LDA) affords carbamoyllithium intermediates that are quenched in situ with various electrophi

PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE

The invention relates toa pharmaceutical composition comprising a pyrazole-O-glucoside derivative selected from the group of compounds (1) to (29) according to claim 1 in combination with at least one second therapeutic agent which is suitable in the trea

METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES

The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for

ACYCLIC IKUR INHIBITORS

A compound of formula I wherein R1, R2, R3, R4 and R5 are described herein.

PYRAZINONES AS CELLULAR PROLIFERATION INHIBITORS

This invention pertains to a method of inhibiting undesired animal cellular proliferation said method comprising contacting an animal cell with a compound of Formula 1 and all pharmaceutically acceptable, salts, N-oxides, hydrates, solvates, or geometric and stereoisomers thereof: Formula (I) wherein R1 is NR4 R5, N=CR19 R21 OR6, G1 or G2; or C1-C8 alkyl, C2-C8 alkenyl, each optionally substituted; A is O, S or NR7; R2 is cyano, NR8-N=CR9 R10 or NC(=O)R30; or a 5- or 6-membered heteroaromatic ring, each ring or ring system optionally substituted; R3 is H, halogen, cyano, C1-C6 alkyl; J is C1- C8 alkyl or phenyl, optionally substituted; and R4, R5, R6, R7, R8, R9, R10, R19, R21, R30, G1 and G2 are defined in the disclosure.